Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jacques Dumas also recently made the following trade(s):

  • On Tuesday, August 22nd, Jacques Dumas sold 17,500 shares of Tetraphase Pharmaceuticals stock. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00.
  • On Thursday, August 17th, Jacques Dumas sold 7,155 shares of Tetraphase Pharmaceuticals stock. The shares were sold at an average price of $5.86, for a total transaction of $41,928.30.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 112.91% and a negative net margin of 2,005.74%. The firm had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. During the same period last year, the business posted ($0.58) earnings per share. The company’s revenue for the quarter was up 355.6% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “Tetraphase Pharmaceuticals Inc (TTPH) Insider Sells $52,762.50 in Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/02/tetraphase-pharmaceuticals-inc-ttph-insider-sells-52762-50-in-stock.html.

Large investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its stake in shares of Tetraphase Pharmaceuticals by 6.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock worth $1,184,000 after purchasing an additional 7,866 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after purchasing an additional 230,420 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Tetraphase Pharmaceuticals by 3.4% in the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock worth $1,726,000 after purchasing an additional 6,114 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Tetraphase Pharmaceuticals by 17.0% in the first quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock worth $2,880,000 after purchasing an additional 45,554 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Tetraphase Pharmaceuticals by 180.4% in the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 408,078 shares during the last quarter. Hedge funds and other institutional investors own 40.92% of the company’s stock.

Several research firms have recently commented on TTPH. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, October 28th. BMO Capital Markets upped their price target on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Finally, ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. Tetraphase Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $12.96.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.